ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies
March 13, 2024 4:02 PM EDTJefferies analyst Kelly Shi lowered the price target on ADC Therapeutics (NYSE: ADCT) to $13.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "Zenlonta FY23 sales of $16.6 had been pre-announced in Jan. and we expect revenue recovery to continue in '24. The... More



